Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis
Alimentary Pharmacology and Therapeutics, Volume 21, No. 7, Year 2005
Notification
URL copied to clipboard!
Description
Aim: To determine efficacy and safety of intravenous micafungin vs. intravenous fluconazole in the treatment of oesophageal candidiasis. Methods: A total of 523 patients ≥16 years with documented oesophageal candidiasis were randomized (1:1) in this controlled, non-inferiority study to receive either micafungin (150 mg/day) or fluconazole (200 mg/day). Response was evaluated clinically and endoscopically. Post-treatment assessments were performed at 2 and 4 weeks after discontinuation of therapy. Results: Median duration of therapy was 14 days. For the primary end-point of endoscopic cure, treatment difference was -0.3% (micafungin 87.7%, fluconazole 88.0%). Documented persistent invasive disease at the end of therapy was reported in 2.7% and 3.9% of patients, respectively. Both 84.8% of micafungin and 88.7% of fluconazole patients remained recurrence free at 4-weeks post-treatment. The overall therapeutic response rate was 87.3% for micafungin and 87.2% for fluconazole. The incidence of drug-related adverse events was 27.7% for micafungin and 21.3% for fluconazole. Six (2.3%) micafungin- and two (0.8%) fluconazole-treated patients discontinued therapy; rash was the most common event leading to discontinuation. Conclusion: Intravenous micafungin (150 mg daily) is well tolerated and as efficacious as intravenous fluconazole (200 mg daily) in the primary treatment of oesophageal candidiasis. achieving high rates of clinical and endoscopic cure. © 2005 Blackwell Publishing Ltd.
Authors & Co-Authors
de Wet, N. T.E.
South Africa, Dundee
Prime Care Clinic
Bester, A. J.
South Africa, Pretoria
Eastmed Medical Centre
Viljoen, Johann J.
South Africa, Bloemfontein
Genclin Corporation
Filho, F.
Brazil, Curitiba
Universidade Federal do Parana
Suleiman, Jamal Muhamad Abdul Hamid
Brazil, Sao Paulo
Instituto de Infectologia Emilio Ribas
Ticona, Eduardo
Peru, Lima
Hospital Nacional Dos de Mayo
Llanos-Cuentas, E. Alejandro
Peru, Lima
Universidad Peruana Cayetano Heredia
Fisco, C.
United States, Northbrook
Astellas Pharma Us, Inc.
Lau, Wendi M.
United States, Northbrook
Astellas Pharma Us, Inc.
Buell, Donald N.
United States, Northbrook
Astellas Pharma Us, Inc.
Statistics
Citations: 128
Authors: 10
Affiliations: 8
Identifiers
Doi:
10.1111/j.1365-2036.2005.02427.x
ISSN:
02692813
Research Areas
Disability
Study Design
Cohort Study